Calycosin protects against chronic prostatitis in rats via inhibition of the p38MAPK/NF-κB pathway.

calycosin chronic prostatitis p38MAPK/NF-κB pathway

Journal

Open medicine (Warsaw, Poland)
ISSN: 2391-5463
Titre abrégé: Open Med (Wars)
Pays: Poland
ID NLM: 101672167

Informations de publication

Date de publication:
2023
Historique:
received: 28 03 2023
revised: 12 06 2023
accepted: 11 07 2023
medline: 4 9 2023
pubmed: 4 9 2023
entrez: 4 9 2023
Statut: epublish

Résumé

Currently, the effect and molecular mechanism of calycosin, the main active ingredient of Qinshi Simiao San, which can alleviate chronic prostatitis (CP), on CP remain unclear. This study aimed to elucidate the potential mechanism of action of calycosin in CP in a rat CP model. The prostate tissue morphology was evaluated based on hematoxylin-eosin staining. Enzyme-linked immunosorbent assay was conducted to evaluate inflammatory cytokine and immune factor levels (secretory immunoglobulin A [SIgA]; immunoglobulin G [IgG]) in prostate tissues and serum. Additionally, representative biomarkers of oxidative stress, including malondialdehyde, superoxide dismutase, and catalase were detected using detection kits, and reactive oxygen species release was evaluated using immunofluorescence staining. Furthermore, the p38 mitogen-activated protein kinase (p38MAPK)/NF-kappaB (NF-κB) signaling pathway was analyzed by western blotting. The results showed that calycosin substantially ameliorated the pathological damage to prostate tissues of the CP rats. Moreover, calycosin significantly downregulated interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha, IgG, and SIgA levels. Furthermore, we found that calycosin considerably suppressed oxidative stress and inhibited the activation of the p38MAPK/NF-κB signaling pathway in rats with CP. In summary, our findings revealed that calycosin protects against CP in rats by inhibiting the p38MAPK/NF-κB pathway.

Identifiants

pubmed: 37663231
doi: 10.1515/med-2023-0770
pii: med-2023-0770
pmc: PMC10473462
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20230770

Informations de copyright

© 2023 the author(s), published by De Gruyter.

Déclaration de conflit d'intérêts

Conflict of interest: The authors declare that they have no competing interests.

Références

Front Pharmacol. 2022 Oct 07;13:970616
pubmed: 36278223
Aging (Albany NY). 2021 Jun 7;13(12):16009-16023
pubmed: 34096887
Prostate. 2018 Aug;78(11):790-800
pubmed: 29654614
BMC Cardiovasc Disord. 2020 Mar 30;20(1):150
pubmed: 32228467
Transl Androl Urol. 2021 May;10(5):1976-1987
pubmed: 34159078
Res Rep Urol. 2019 Jun 04;11:165-174
pubmed: 31240202
Neurochem Res. 2021 Sep;46(9):2262-2275
pubmed: 34075523
Antioxid Redox Signal. 2015 Apr 1;22(10):832-47
pubmed: 25602783
Curr Issues Mol Biol. 2021 Oct 24;43(3):1741-1755
pubmed: 34889889
Aging Male. 2020 Dec;23(5):1004-1008
pubmed: 31397617
Andrologia. 2021 Sep;53(8):e14113
pubmed: 33979463
Biomed Pharmacother. 2022 Sep;153:113418
pubmed: 36076540
Pain. 2017 Aug;158(8):1517-1527
pubmed: 28715352
J Immunol Res. 2022 Jun 17;2022:6833867
pubmed: 35755168
Redox Rep. 2021 Dec;26(1):1-9
pubmed: 33416009
Evid Based Complement Alternat Med. 2022 Jan 12;2022:7098121
pubmed: 35069766
Biomed Pharmacother. 2018 Sep;105:599-605
pubmed: 29890468
Arch Oral Biol. 2022 Sep;141:105498
pubmed: 35810494
Biomed Pharmacother. 2018 Oct;106:714-723
pubmed: 29990863
Food Chem Toxicol. 2021 Sep;155:112382
pubmed: 34216712
J Cell Mol Med. 2020 Oct;24(19):11084-11099
pubmed: 32910538
Pain. 2016 Mar;157(3):585-597
pubmed: 26882345
Andrology. 2020 May;8(3):747-755
pubmed: 31880092
Inflammopharmacology. 2017 Dec;25(6):595-607
pubmed: 28929423
Zhonghua Nan Ke Xue. 2020 Jun;26(6):559-563
pubmed: 33356047
Diseases. 2017 Nov 08;5(4):
pubmed: 29117111
Oxid Med Cell Longev. 2021 Mar 2;2021:6687493
pubmed: 33815658
Int J Mol Sci. 2019 Dec 24;21(1):
pubmed: 31878204
Urologiia. 2021 Sep;(4):138-144
pubmed: 34486287
Food Chem Toxicol. 2018 Jun;116(Pt B):152-160
pubmed: 29608980
Pak J Pharm Sci. 2020 May;33(3(Special)):1341-1347
pubmed: 33361020
Biochem Pharmacol. 2002 Jan 15;63(2):305-20
pubmed: 11841806

Auteurs

Heng Wang (H)

Department of Urology, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang 222000, China.

Lei He (L)

Department of Acupuncture, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang 222000, China.

Zhaofei Liu (Z)

Department of Urology, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang 222000, China.

Xiangjun Xu (X)

Department of Urology, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang 222000, China.

Haitao Zhang (H)

Department of Urology, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang 222000, China.

Pengfei Mao (P)

Department of Urology, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Lianyungang 222000, China.

Ming Li (M)

Department of Pharmacy, Lianyungang TCM Hospital Affiliated to Nanjing University of Chinese Medicine, No.160 Chaoyang Middle Road, Haizhou District, Lianyungang 222000, China.

Classifications MeSH